US20180185341A1 - Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors - Google Patents

Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors Download PDF

Info

Publication number
US20180185341A1
US20180185341A1 US15/516,443 US201515516443A US2018185341A1 US 20180185341 A1 US20180185341 A1 US 20180185341A1 US 201515516443 A US201515516443 A US 201515516443A US 2018185341 A1 US2018185341 A1 US 2018185341A1
Authority
US
United States
Prior art keywords
alkyl
ring
alkoxy
heterocyclic ring
haloc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/516,443
Other languages
English (en)
Inventor
Nicole Buschmann
Robin Alec Fairhurst
Pascal Furet
Diana Graus Porta
Carolina Haefliger
Bo Han
Thomas Knöpfel
Catherine Leblanc
Lv LIAO
Robert Mah
Masato Murakami
Pierre Nimsgern
Michael Palmer
Dale Porter
Sebastien Ripoche
Can Wang
Youzhen Wang
Andreas Weiss
Jing Xiong
Xianglin ZHAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Novartis Institutes for Biomedical Research Inc
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Assigned to NOVARTIS PHARMA AG reassignment NOVARTIS PHARMA AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RIPOCHE, Sebastien, MAH, ROBERT, FURET, PASCAL, MURAKAMI, MASATO, GRAUS PORTA, DIANA, WEISS, ANDREAS, HAEFLIGER, CAROLINA, LEBLANC, CATHERINE, BUSCHMANN, NICOLE, FAIRHURST, ROBIN ALEC, KNOEPFEL, THOMAS, NIMSGERN, Pierre
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS PHARMA AG
Assigned to BEIJING NOVARTIS PHARMA CO. LTD. reassignment BEIJING NOVARTIS PHARMA CO. LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: XIONG, Jing, LIAO, Lv
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BEIJING NOVARTIS PHARMA CO. LTD.
Assigned to NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. reassignment NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PALMER, MICHAEL, WANG, YOUZHEN, PORTER, DALE
Assigned to SUZHOU NOVARTIS PHARMA TECHNOLOGY CO., LTD. reassignment SUZHOU NOVARTIS PHARMA TECHNOLOGY CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAN, BO, WANG, CAN, ZHAO, Xianglin
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SUZHOU NOVARTIS PHARMA TECHNOLOGY CO., LTD.
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.
Publication of US20180185341A1 publication Critical patent/US20180185341A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention provides the use of bicyclic pyridyl derivatives compounds in methods of treating disease.
  • Fibroblast Growth Factors constitute a family of over twenty structurally related polypeptides that are developmentally regulated and expressed in a wide variety of tissues. FGFs stimulate proliferation, cell migration and differentiation and play a major role in skeletal and limb development, wound healing, tissue repair, hematopoiesis, angiogenesis, and tumorigenesis (reviewed in Ornitz, Novartis Found Symp 232: 63-76; discussion 76-80, 272-82 (2001)).
  • FGFs The biological action of FGFs is mediated by specific cell surface receptors belonging to the Receptor Protein Tyrosine Kinase (RPTK) family of protein kinases. These proteins consist of an extracellular ligand binding domain, a single transmembrane domain and an intracellular tyrosine kinase domain which undergoes phosphorylation upon binding of FGF.
  • RPTK Receptor Protein Tyrosine Kinase
  • FGFR1 also called Flg, fms-like gene, flt-2, bFGFR, N-bFGFR or Cek1
  • FGFR2 also called Bek-Bacterial Expressed Kinase-, KGFR, Ksam, Ksaml and Cek3
  • FGFR3 also called Cek2
  • FGFR4 FGFR4
  • FGFRs All mature FGFRs share a common structure consisting of an amino terminal signal peptide, three extracellular immunoglobulin-like domains (Ig domain I, Ig domain II, Ig domain Ill), with an acidic region between Ig domains (the “acidic box” domain), a transmembrane domain, and intracellular kinase domains (Ullrich and Schlessinger, Cell 61: 203, 1990; Johnson and Williams (1992) Adv. Cancer Res. 60: 1-41).
  • the distinct FGFR isoforms have different binding affinities for the different FGF ligands.
  • FGFR4 may play an important role in liver cancer in particular (PLoS One, 2012, volume 7, 36713).
  • Other studies have also implicated FGFR4 or its ligand FGF19 in other cancer types including breast, glioblastoma, prostate, rhabdomyosarcoma, gastric, ovarian, lung, colon (Int. J.
  • FGFR4 blocking antibodies have been described for instance in WO2009/009173, WO2007/136893, WO2012/138975, WO2010/026291, WO2008/052798 and WO2010/004204.
  • WO2014/144737 and WO2014/011900 also describe low molecular weight FGFR4 inhibitors.
  • the present invention aims to address the need for more adapted and effective treatment regimens using FGFR4 inhibitors.
  • the invention provides compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, which compounds are FGFR4 inhibitors, for use in methods of treating, preventing, or ameliorating cancers.
  • the invention relates to methods of treating, preventing or ameliorating solid malignancies in a patient, wherein the solid malignancies are characterized by positive expression of certain biomarkers.
  • the invention provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof
  • V is selected from CH 2 , O, CH(OH); W is selected from CH 2 , CH 2 CH 2 , bond;
  • X is C(R X ) or N;
  • Y is C(R Y ) or N;
  • Z is CH or N
  • R X is selected from hydrogen, halogen, haloC 1 -C 3 alkyl, cyano, C 1 -C 6 alkyl, hydroxyC 1 -C 6 alkyl
  • R Y is selected from hydrogen, halogen, C 1 -C 3 alkyl, C 1 -C 6 alkoxy, hydroxyC 1 -C 3 alkoxy, NR Y1 R Y2 , cyano, C 1 -C 3 alkoxyC 1 -C 3 alkoxy, C 1 -C 3 alkoxy-haloC 1 -C 3 alkoxy, di(C 1 -C 3 alkyl)aminoC 1 -C 6 alkoxy, O—(CH 2 ) 0-1 —R Y3 , CR Y6 R Y7 , S—
  • the terms “compounds of the present invention” or “compounds of the invention” or “compounds used in the present invention” refer to compounds of formula (I), (Ia), (Ia-1) and salts thereof as defined herein, as well as all stereoisomers (including diastereoisomers and enantiomers), rotamers, tautomers, isomeric internal addition products and isotopically labeled compounds (including deuterium substitutions), as well as inherently formed moieties.
  • a compound of formula (I) refers to:
  • V is selected from CH 2 , O, CH(OH); W is selected from CH 2 , CH 2 CH 2 , bond;
  • X is C(R X ) or N;
  • Y is C(R Y ) or N;
  • Z is CH or N
  • R X is selected from hydrogen, halogen, haloC 1 -C 3 alkyl, cyano, C 1 -C 6 alkyl, hydroxyC 1 -C 6 alkyl
  • R Y is selected from hydrogen, halogen, C 1 -C 3 alkyl, C 1 -C 6 alkoxy, hydroxyC 1 -C 3 alkoxy, NR Y1 R Y2 , cyano, C 1 -C 3 alkoxyC 1 -C 3 alkoxy, C 1 -C 3 alkoxy-haloC 1 -C 3 alkoxy, di(C 1 -C 3 alkyl)aminoC 1 -C 6 alkoxy, O—(CH 2 ) 0-1 —R Y3 , CR Y6 R Y7 , S—
  • R X is selected from hydrogen, halogen, haloC 1 -C 3 alkyl, cyano, C 1 -C 6 alkyl, hydroxyC 1 -C 6 alkyl
  • R Y is selected from hydrogen, halogen, C 1 -C 3 alkyl, C 1 -C 6 alkoxy, hydroxyC 1 -C 3 alkoxy, NR Y1 R Y2 , cyano, C 1 -C 3 alkoxyC 1 -C 3 alkoxy, C 1 -C 3 alkoxy-haloC 1 -C 3 alkoxy, di(C 1 -C 3 alkyl)aminoC 1 -C 6 alkoxy, O—(CH 2 ) 0-1 —R Y3 , CR Y6 R Y7 , S—C 1 -C 3 alkyl, haloC 1 -C 6 alkoxy optionally substituted with hydroxy; or R X and R Y together with the ring to which they
  • a compound of formula (Ia-1) refers to:
  • R Y is selected from hydrogen, halogen, C 1 -C 3 alkyl, C 1 -C 6 alkoxy, hydroxyC 1 -C 3 alkoxy, NR Y R Y2 , cyano, C 1 -C 3 alkoxyC 1 -C 3 alkoxy, C 1 -C 3 alkoxy-haloC 1 -C 3 alkoxy, di(C 1 -C 3 alkyl)aminoC 1 -C 6 alkoxy, O—(CH 2 ) 0-1 —R Y3 , CR Y6 R Y7 , S—C 1 -C 3 alkyl, haloC 1 -C 6 alkoxy optionally substituted with hydroxy; R Y1 is hydrogen and R Y2 is selected from C 1 -C 6 alkyl; hydroxyC 1 -C 6 alkyl; haloC 1 -C 6 alkyl optionally substituted with hydroxyl; C 1 -C 4 alkoxyC 1
  • compounds of the invention where R 1 is hydroxymethyl, CH 2 CO 2 H, 4-piperidinyl e.g. compounds (I-1), (I-2) and (I-5), may be in the form as depicted below (compounds (I-1a), (I-2a) and (1-5a)).
  • C 1 -C 6 alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to six carbon atoms, and which is attached to the rest of the molecule by a single bond.
  • C 1 -C 4 alkyl is to be construed accordingly.
  • C 1 -C 3 alkyl is to be construed accordingly.
  • C 1 -C 6 alkyl examples include, but are not limited to, methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl, n-pentyl and 1,1-dimethylethyl (t-butyl).
  • hydroxyC 1 -C 6 alkyl refers to a radical of formula —R a —OH, wherein R a is C 1-6 alkyl as defined above.
  • R a is C 1-6 alkyl as defined above.
  • Examples of hydroxyC 1 -C 6 alkyl include, but are not limited to, hydroxy-methyl, 2-hydroxy-ethyl, 2-hydroxy-propyl, 3-hydroxy-propyl and 5-hydroxy-pentyl.
  • C 3 -C 6 cycloalkyl refers to saturated monocyclic hydrocarbon groups of 3-6 carbon atoms.
  • Examples of C 3 -C 6 cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • C 1 -C 6 alkoxy refers to a radical of the formula —OR a where R a is a C 1 -C 6 alkyl radical as generally defined above.
  • R a is a C 1 -C 6 alkyl radical as generally defined above.
  • C 1 -C 3 alkoxy is to be construed accordingly.
  • C 1 -C 6 alkoxy examples include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy, and hexoxy.
  • C 1 -C 4 alkoxyC 1 -C 6 alkyl refers to a radical of the formula —R b —O—R a where R a is a C 1 -C 4 alkyl radical and R b is a C 1 -C 6 alkyl radical as defined above.
  • the term “C 1 -C 3 alkoxyC 1 -C 6 alkyl” is to be construed accordingly.
  • the oxygen atom may be bonded to any carbon atom in either alkyl radical.
  • C 1 -C 4 alkoxyC 1 -C 6 alkyl examples include, but are not limited to, methoxy-methyl, methoxy-ethyl, ethoxy-ethyl, 1-ethoxy-propyl and 2-methoxy-butyl.
  • Halogen or “halo” refers to bromo, chloro, fluoro or iodo.
  • halogenC 1 -C 6 alkyl or “haloC 1 -C 6 alkyl” refers to C 1 -C 6 alkyl radical, as defined above, substituted by one or more halo radicals, as defined above.
  • halogenC 1 -C 6 alkyl include, but are not limited to, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, 3-bromo-2-fluoropropyl and 1-bromomethyl-2-bromoethyl.
  • haloC 1 -C 3 alkoxy refers to C 1 -C 3 alkoxy as defined above, substituted by one or more halo radicals, as defined above.
  • haloC 1 -C 3 alkoxy include, but are not limited to, trifluoromethoxy, difluoromethoxy, trifluoroethoxy.
  • hydroxyC 1 -C 3 alkoxy refers to a C 1 -C 3 alkoxy radical as defined above, wherein one of the hydrogen atoms of the C 1 -C 3 alkoxy radical is replaced by OH.
  • hydroxyC 1 -C 3 alkoxy include, but are not limited to, hydroxymethoxy, hydroxyethoxy.
  • C 1 -C 3 alkoxyC 1 -C 3 alkoxy refers to a C 1 -C 3 alkoxy radical as defined above, wherein one of the hydrogen atoms of the C 1-3 alkoxy radical is replaced by —O—C 1 -C 3 alkyl.
  • Examples of C 1 -C 3 alkoxyC 1 -C 3 alkoxy include, but are not limited to, methoxymethoxy, ethoxymethoxy.
  • C 1 -C 3 alkoxy-haloC 1 -C 3 alkoxy refers to a haloC 1 -C 3 alkoxy radical as defined above, wherein one of the hydrogen atoms of the haloC 1 -C 3 alkoxy radical is replaced by —O—C 1 -C 3 alkyl.
  • Examples of C 1 -C 3 alkoxy-haloC 1 -C 3 alkoxy include, but are not limited to, methoxytrifluoropropyloxy.
  • di(C 1 -C 3 alkyl)aminoC 1 -C 6 alkyl refers to a radical of the formula —R a1 —N(R a2 )—R a2 where R a1 is a C 1 -C 6 alkyl radical as defined above and each R a2 is a C 1 -C 3 alkyl radical, which may be the same or different, as defined above.
  • the nitrogen atom may be bonded to any carbon atom in any alkyl radical.
  • the “diC 1 -C 3 alkylaminoC 1 -C 6 alkyl” may be substituted with hydroxy.
  • di(C 1 -C 3 alkyl)aminoC 1 -C 6 alkoxy refers to a radical of the formula —R a1 —N(R a2 )—R a2 where R a1 is a C 1 -C 6 alkoxy radical as defined above and each R a2 is a C 1 -C 3 alkyl radical, which may be the same or different, as defined above.
  • 6-membered saturated heterocyclic ring comprising one heteroatom selected from N, O or S includes piperidyl, tetrahydropyranyl and tetrahydrothiopyranyl.
  • 6-membered unsaturated non-aromatic heterocyclic ring comprising one heteroatom selected from N, O or S includes, but is not limited to, tetrahydropyridinyl, dihydropyranyl, dihydrothiopyranyl.
  • a 4-, 5-, or 6-membered saturated heterocyclic ring comprising at least one heteroatom selected from N, O or S includes as examples, but is not limited to, azetidinyl, oxetanyl, pyrrolidyl, tetrahydrofuryl, tetrahydrothienyl, piperidyl, piperazinyl, tetrahydropyranyl, morpholinyl.
  • 5-membered saturated heterocyclic ring includes as example, but is not limited to, pyrrolidine.
  • a saturated 5- or 6-membered ring optionally comprising one additional heteroatom selected from N, O or S includes as examples, but is not limited to, pyrrolidine, oxazolidine, piperazine, morpholine, thiomorpholine rings.
  • a “4-, 5- or 6-membered non-aromatic heterocyclic ring comprising at least one heteroatom selected from N, O or S” includes 4-, 5-, or 6-membered saturated heterocyclic ring comprising at least one heteroatom selected from N, O or S as defined herein. It also includes 4-, 5-, or 6-membered unsaturated heterocyclic ring comprising at least one heteroatom selected from N, O or S.
  • bicyclic aromatic ring system optionally further comprising one or two heteroatoms selected from N, O or S” includes, but is not limited to, imidazopyridine and isothiazolopyridine.
  • bicycloC 5 -C 8 alkyl refers to bicyclic hydrocarbon groups comprising 5 to 8 carbon atoms including, but not limited to, bicyclo[2.1.1]hexyl, bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octyl.
  • R Y , R X and R Y together, R Y2 , R Y3 , R Y4 includes unsubstituted or substituted once or twice.
  • substituted as used herein, includes substituted once or twice, preferably once.
  • substituent R 4 when referring to substituent R 4 , includes 2, 3, 4, 5, or 6 times. Preferably, it includes 2 or 3 times.
  • solid malignancies refers to non-hematological malignancies.
  • FGFR4 refers to fibroblast growth factor receptor 4, also known as CD334, JTK2, TKF (gene ID: 2264).
  • FGF19 refers to fibroblast growth factor 19 (gene ID: 9965)
  • KLB refers to the beta-klotho protein (gene ID: 152831).
  • biomarkers of the invention refers to any of FGFR4, KLB and FGF19.
  • Any positive expression in FGFR4, KLB and/or FGF19 as described herein can be assessed by methods known to the skilled person such as e.g. RT-qPCR, Western blotting, ELISA, immunohistochemistry.
  • any positive expression in FGFR4, KLB and/or FGF19 can be assayed by detecting for expression of the RNA levels of FGFR4, KLB and/or FGF19 or detecting expression of the FGFR4, KLB and/or FGF19 protein product by methods known to the skilled person. It is within the reach of the skilled person to determine a positive expression of FGFR4, FGF19 and/or KLB.
  • the positive expression in FGFR4, KLB and/or FGF19 can be assessed as described in the examples.
  • test is used to refer to the act of identifying, screening, probing or determining, which act may be performed by any conventional means. For example, a sample may be assayed for the presence of a particular biomarker by using an ELISA assay, a Northern blot, imaging, etc. to detect whether a specific biomarker is present in the sample.
  • the terms “assaying” and “determining” contemplate a transformation of matter, e.g., a transformation of a biological sample, e.g., a blood sample or other tissue sample, from one state to another by means of subjecting that sample to physical testing. Further, as used herein, the terms “assaying” and “determining” are used to mean testing and/or measuring.
  • the phrase “assaying a biological sample from the patient for the presence or the positive expression of FGF19 or FGF19 and KLB or FGFR4, FGF19 and/or KLB” and the like is used to mean that a sample may be tested (either directly or indirectly) for either the presence or absence of a given biomarker or for the level of a particular biomarker. It will be understood that the positive expression of a biomarker FGFR4, KLB and/or FGF19 in a substance denotes one probability and the absence of a substance denotes a different probability, then either the presence or the absence of such substance may be used to guide a therapeutic decision.
  • selecting and “selected” in reference to a patient is used to mean that a particular patient is specifically chosen from a larger group of patients on the basis of (due to) the particular patient having a predetermined criteria.
  • selecting refers to providing treatment to a patient having a particular disease, where that patient is specifically chosen from a larger group of patients on the basis of the particular patient having a predetermined criterion.
  • selective administering refers to administering a drug to a patient that is specifically chosen from a larger group of patients on the basis of (due to) the particular patient having a predetermined criterion.
  • selectively treating and selectively administering it is meant that a patient is delivered a personalized therapy based on the patient's particular biology, rather than being delivered a standard treatment regimen based solely on the patient having a particular disease.
  • Selecting in reference to a method of treatment as used herein, does not refer to fortuitous treatment of a patient that has the biomarker, but rather refers to the deliberate choice to administer treatment to a patient based on the patient having positive expression of the biomarker.
  • selective treatment differs from standard treatment, which delivers a particular drug to all patients, regardless of their biomarker.
  • “likelihood” and “likely” is a measurement of how probable an event is to occur. It may be used interchangeably with “probability”. Likelihood refers to a probability that is more than speculation, but less than certainty. Thus, an event is likely if a reasonable person using common sense, training or experience concludes that, given the circumstances, an event is probable. In some embodiments, once likelihood has been ascertained, the patient may be treated (or treatment continued, or treatment proceed with a dosage increase) with the test compound. In one embodiment, the “likelihood” and “likely” denote a chance in percent of how probable an event is to occur.
  • the phrase “increased likelihood” refers to an increase in the probability that an event will occur.
  • some methods herein allow prediction of whether a patient will display an increased likelihood of responding to treatment with the test molecule or an increased likelihood of responding better to treatment with the test molecule.
  • the increased likelihood means that there is more than 50% chance, more than 60% chance, more than 70% or more than 80% chance that an event will occur.
  • a decreased likelihood means, that the chance is lower than 50%, lower than 60%, lower than 70% or lover than 80%, respectively, that an event will occur.
  • a compound of formula (Ia) or a pharmaceutically acceptable salt thereof for use in the treatment of solid malignancies characterized by positive FGFR4 and KLB expression, or positive FGFR4 and FGF19 expression, or positive FGFR4, KLB and FGF19 expression.
  • R X is selected from halogen, haloC 1 -C 3 alkyl, cyano
  • R Y is selected from hydrogen, halogen, C 1 -C 3 alkyl, C 1 -C 6 alkoxy, haloC 1 -C 3 alkoxy, hydroxyC 1 -C 3 alkoxy, NR Y1 R Y2 , C 1 -C 3 alkoxyC 1 -C 3 alkoxy, C 1 -C 3 alkoxy-haloC 1 -C 3 alkoxy, O—(CH 2 ) 0-1 —R Y3 ;
  • R Y1 is hydrogen and R Y2 is selected from C 1 -C 6 alkyl, hydroxyC 1 -C 6 alkyl, C 1 -C 3 alkoxyC 1 -C 6 alkyl, (CH 2 ) 0-1 —R Y4 , haloC 1 -C 6 alkyl optionally substituted with hydroxyl;
  • a compound of formula (Ia-1) or a pharmaceutically acceptable salt thereof for use in the treatment of solid malignancies characterized by positive FGFR4 and KLB expression, or positive FGFR4 and FGF19 expression, or positive FGFR4, KLB and FGF19 expression.
  • R Y is selected from hydrogen, halogen, C 1 -C 3 alkyl, C 1 -C 6 alkoxy, haloC 1 -C 3 alkoxy, hydroxyC 1 -C 3 alkoxy, NR Y1 R Y2 , C 1 -C 3 alkoxyC 1 -C 3 alkoxy, C 1 -C 3 alkoxy-haloC 1 -C 3 alkoxy, O—(CH 2 ) 0-1 —R Y3 ;
  • R Y1 is hydrogen and R Y2 is C 1 -C 6 alkyl, hydroxyC 1 -C 6 alkyl, C 1 -C 4 alkoxyC 1 -C 6 alkyl, (CH 2 ) 0-1 —R Y4 , haloC 1 -C 6 alkyl optionally substituted with hydroxyl;
  • R Y3 is a 4-, 5- or 6-membered saturated heterocyclic ring comprising at least one heteroatom selected from N, O
  • R Y is selected from NR Y1 R Y2 , C 1 -C 3 alkoxyC 1 -C 3 alkoxy, O—(CH 2 ) 0-1 —R Y3 ;
  • R Y1 is hydrogen and R Y2 is selected from C 1 -C 6 alkyl; hydroxyC 1 -C 6 alkyl; haloC 1 -C 6 alkyl optionally substituted with hydroxyl; C 1 -C 4 alkoxyC 1 -C 6 alkyl; haloC 1 -C 3 alkoxyC 1 -C 6 alkyl; (CH 2 ) 0-1 —R Y4 ; di(C 1 -C 3 alkyl)aminoC 1 -C 6 alkyl substituted with hydroxy; bicycloC 5 -C 8 alkyl optionally substituted with hydroxyC 1 -C 3 alkyl; phenyl substituted with S(O) 2 —CH(CH 3 ) 2 ; C 2
  • R Y is selected from NR Y1 R Y2 , C 1 -C 3 alkoxyC 1 -C 3 alkoxy, O—(CH 2 ) 0-1 —R Y3 ;
  • R Y3 is a 4-, 5- or 6-membered saturated heterocyclic ring comprising at least one heteroatom selected from N, O or S, which ring is optionally substituted with C 1 -C 3 alkyl;
  • R Y1 is hydrogen and R Y2 is C 1 -C 6 alkyl, C 1 -C 3 alkoxyC 1 -C 6 alkyl, (CH 2 ) 0-1 —R Y4 ;
  • R Y4 is a 4-, 5-, or 6-membered saturated heterocyclic ring comprising at least one heteroatom selected from N, O or S, which ring is optionally substituted with C 1 -C 3 alkyl;
  • R 1 is selected from hydrogen, halogen, C 1 -C 3 alkyl, halo
  • R Y is selected from NR Y1 R Y2 , C 1 -C 3 alkoxyC 1 -C 3 alkoxy;
  • R 1 is hydrogen and
  • R Y2 is selected from C 1 -C 6 alkyl; hydroxyC 1 -C 6 alkyl; haloC 1 -C 6 alkyl optionally substituted with hydroxyl; C 1 -C 4 alkoxyC 1 -C 6 alkyl; haloC 1 -C 3 alkoxyC 1 -C 6 alkyl; (CH 2 ) 0-1 —R Y4 ; di(C 1 -C 3 alkyl)aminoC 1 -C 6 alkyl substituted with hydroxy; bicycloC 5 -C 8 alkyl optionally substituted with hydroxyC 1 -C 3 alkyl; phenyl substituted with S(O) 2 —CH(CH 3 ) 2 ; C 2 -C 3 alkylsulfonic acid; or R Y1
  • R Y is selected from NR Y1 R Y2 , C 1 -C 3 alkoxyC 1 -C 3 alkoxy;
  • R Y1 is hydrogen and R Y2 is selected from C 1 -C 6 alkyl, C 1 -C 3 alkoxyC 1 -C 6 alkyl, (CH 2 ) 0-1 —R Y4 ;
  • R Y4 is a 4-, 5-, or 6-membered saturated heterocyclic ring comprising at least one heteroatom selected from N, O or S, which ring is optionally substituted with C 1 -C 3 alkyl;
  • R 1 is selected from CH 2 NR 2 R 3 , CH(CH 3 )NR 2 R 3 ;
  • R 2 is C 1 -C 3 alkyl and R 3 is selected from C 1 -C 3 alkyl, C(O)—C 1 -C 3 alkyl or R 2 and R 3 together with the N atom to which they are attached form a saturated 5- or 6-membered
  • the compound of formula (I), (Ia) or (Ia-1) used in the present invention is selected from
  • N-(5-cyanopyridin-2-yl)-7-formyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide or a pharmaceutically acceptable salt thereof for use in the treatment of solid malignancies characterized by positive FGFR4 and KLB expression.
  • N-(5-cyanopyridin-2-yl)-7-formyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide or a pharmaceutically acceptable salt thereof for use in the treatment of solid malignancies characterized by positive FGFR4 and FGF19 expression.
  • N-(5-cyanopyridin-2-yl)-7-formyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide or a pharmaceutically acceptable salt thereof for use in the treatment of solid malignancies characterized by positive FGFR4, KLB and FGF19 expression.
  • N-(5-cyanopyridin-2-yl)-7-formyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide or a pharmaceutically acceptable salt thereof for use in the treatment of liver cancer, breast cancer, glioblastoma, prostate cancer, rhabdomyosarcoma, gastric cancer, ovarian cancer, lung cancer or colon cancer characterized by positive FGFR4 and FGF19 expression.
  • N-(5-cyanopyridin-2-yl)-7-formyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide or a pharmaceutically acceptable salt thereof for use in the treatment of liver cancer, breast cancer, glioblastoma, prostate cancer, rhabdomyosarcoma, gastric cancer, ovarian cancer, lung cancer or colon cancer characterized by positive FGFR4, KLB and FGF19 expression.
  • a compound of formula (I), (Ia) or (Ia-1) or a pharmaceutically acceptable salt thereof for use in treating a patient having solid malignancies characterized in that the compound of formula (I) or a pharmaceutically acceptable salt thereof is to be administered to the patient on the basis of said patient having positive FGFR4 and KLB expression, or positive FGFR4 and FGF19 expression, or positive FGFR4, KLB and FGF19 expression.
  • a compound of formula (I), (Ia) or (Ia-1) or a pharmaceutically acceptable salt thereof for use in treating a patient having solid malignancies characterized in that
  • a compound of formula (I), (Ia) or (Ia-1) or a pharmaceutically acceptable salt thereof for use in treating a patient having solid malignancies characterized in that
  • a compound of formula (I), (Ia) or (Ia-1) or a pharmaceutically acceptable salt thereof for use in treating a patient having solid malignancies comprising
  • the invention relates to a method of treating a patient having solid malignancies characterized by positive FGFR4 and KLB expression comprising administering to said patient a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.
  • the invention relates to a method of treating a patient having solid malignancies characterized by positive FGFR4 and FGF19 expression comprising administering to said patient a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.
  • the invention relates to a method of treating a patient having solid malignancies characterized by positive FGFR4, KLB and FGF19 expression comprising administering to said patient a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.
  • the invention relates to a method of selectively treating a patient having solid malignancies, comprising selectively administering a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof to the patient on the basis of the patient having solid malignancies characterized by positive FGFR4 and KLB expression, or positive FGFR4 and FGF19 expression, or positive FGFR4, KLB and FGF19 expression.
  • the invention relates to a method of selectively treating a patient having solid malignancies with a compound of the present invention or a pharmaceutically acceptable salt thereof comprising
  • the invention relates to a method of selectively treating a patient having solid malignancies, comprising
  • the invention relates to a method of selectively treating a patient having solid malignancies, comprising:
  • the biological sample is selected from blood, plasma and tissue sample.
  • the positive expression of FGF19 is assayed from a blood sample.
  • the positive expression of FGF19 is assayed from a tissue sample.
  • the positive expression of FGFR4 or KLB is assayed from a tissue sample.
  • the methods of the invention include detecting expression of the biomarker gene product (i.e. FGFR4, KLB, FGF19 gene products) in a sample taken from a patient having solid malignancies and can be performed by detecting, for example, RNA transcribed from the biomarker gene such as mRNA, or polypeptides encoded by the biomarker gene.
  • the level of expression of the biomarker can be used to predict whether a patient will likely respond to a compound as described herein. Those patients that have an increased level of expression of the biomarker compared to a control (referred to also herein as patients having a “positive expression of the biomarker”) are selected for treatment with the compound described herein as it is predicted that such a patient has an increased likelihood of responding to such compounds.
  • any appropriate sample of cells taken from a patient having solid malignancies can be used.
  • the sample of cells or tissue sample will be obtained from the subject with solid malignancies by biopsy or surgical resection.
  • the sample taken from the patient having solid malignancies may be a blood sample.
  • the sample of, for example tissue may also be stored in, e.g., RNA later (Ambion; Austin Tex.) or flash frozen and stored at ⁇ 80° C. for later use.
  • the biopsied tissue sample may also be fixed with a fixative, such as formaldehyde, paraformaldehyde, or acetic acid/ethanol.
  • the fixed tissue sample may be embedded in wax (paraffin) or a plastic resin.
  • RNA or protein may also be extracted from a fixed or wax-embedded tissue sample or a frozen tissue sample. Once a sample of cells or sample of tissue is removed from the subject with cancer, it may be processed for the isolation of RNA or protein using techniques well known in the art and as described below.
  • RNA from a biopsy taken from a patient with solid malignancies can include, for example, guanidium thiocyanate lysis followed by CsCl centrifugation (Chirgwin, et al., Biochemistry 18:5294-5299, 1979).
  • RNA from single cells may be obtained as described in methods for preparing cDNA libraries from single cells (see, e.g., Dulac, Curr. Top. Dev. Biol. 36:245, 1998; Jena, et al., J. Immunol. Methods 190:199, 1996).
  • the RNA population may be enriched for sequences of interest.
  • Enrichment may be accomplished, for example, by random hexamers and primer-specific cDNA synthesis, or multiple rounds of linear amplification based on cDNA synthesis and template-directed in vitro transcription (see, e.g., Wang, et al., Proc. Natl. Acad. Sci. USA 86:9717, 1989; Dulac, et al., supra; Jena, et al., supra).
  • the assaying method includes providing a nucleic acid probe comprising a nucleotide sequence, for example, at least 10, 15, 25 or 40 nucleotides, and up to all or nearly all of the coding sequence which is complementary to a portion of the coding sequence of a nucleic acid sequence of FGFR4, KLB and FGF19; obtaining a tissue sample from a mammal having a cancerous cell; contacting the nucleic acid probe under stringent conditions with RNA obtained from a biopsy taken from a patient (e.g., in a Northern blot, in situ hybridization assay, PCR etc); and determining the amount of hybridization of the probe with RNA.
  • Nucleic acids may be labeled during or after enrichment and/or amplification of RNAs.
  • the step of assaying may comprise a technique as described below. Further examples of assaying are described in the examples.
  • the biomarkers FGFR4, KLB and FGF19 can be assayed using any method known in the art such as reverse Transcriptase PCR (RT-PCR).
  • RT-PCR reverse Transcriptase PCR
  • This method includes isolating mRNA using any technique known in the art, e.g., by using a purification kit, buffer set and protease from commercial manufacturers, such as Qiagen.
  • the reverse transcription step is typically primed using specific primers, random hexamers, or oligo-dT primers, depending on the circumstances and the goal of expression profiling and the cDNA derived can then be used as a template in the subsequent PCR reaction.
  • TaqMan(R) RT-PCR can then be performed using, e.g., commercially available equipment.
  • RT-PCR measures PCR product accumulation through a dual-labeled fluorigenic probe (e.g., using TaqMan® probe).
  • Real time PCR is compatible both with quantitative competitive PCR, where internal competitor for each target sequence is used for normalization, and with quantitative comparative PCR using a normalization gene contained within the sample, or a housekeeping gene for RT-PCR.
  • quantitative competitive PCR where internal competitor for each target sequence is used for normalization
  • quantitative comparative PCR using a normalization gene contained within the sample or a housekeeping gene for RT-PCR.
  • microarrays which include one or more probes corresponding to one or more of genes FGFR4, KLB and FGF19.
  • the method includes the production of hybridization patterns of labeled target nucleic acids on the array surface.
  • the resultant hybridization patterns of labeled nucleic acids may be visualized or detected in a variety of ways, with the particular manner of detection selected based on the particular label of the target nucleic acid.
  • Representative detection means include scintillation counting, autoradiography, fluorescence measurement, calorimetric measurement, light emission measurement, light scattering, and the like.
  • a TaqMan® Low Density Array (TLDA) card can be used which can include one or more probes corresponding to one or more of genes FGFR4, KLB and FGF19.
  • TLDA TaqMan® Low Density Array
  • the method of detection utilizes an array scanner that is commercially available (Affymetrix, Santa Clara, Calif.).
  • the scanner is controlled from a system computer with an interface and easy-to-use software tools.
  • the output may be directly imported into or directly read by a variety of software applications. Scanning devices are described in, for example, U.S. Pat. Nos. 5,143,854 and 5,424,186.
  • a control for comparison can be determined by one skilled in the art.
  • a control is determined by choosing an expression value that serves as a cut-off value such that the value differentiates between those test samples that have increased biomarker expression, positive expression, from those that do not.
  • the control can be a test sample taken from a healthy person or a sample such as a tumor sample where the biomarkers do not show expression or do not have increased expression above a normal/basal level.
  • the expression of each biomarker is measured and can be converted into an expression value after normalization by the expression level of a housekeeping gene. These expression values then can be used to generate a score which is then compared against a cut-off to select which subjects have positive biomarker expression and therefore are likely to benefit from treatment with compound as described herein.
  • the presence of a protein product encoded by the biomarkers can be assayed using any appropriate method known in the art and the level of protein product can be compared to a control.
  • exemplary immunoassays include fluorescence polarization immunoassay (FPIA) 5 fluorescence immunoassay (FIA), enzyme immunoassay (EIA), nephelometric inhibition immunoassay (NIA), enzyme-linked immunosorbent assay (ELISA), and radioimmunoassay (RIA).
  • FPIA fluorescence polarization immunoassay
  • FIA fluorescence immunoassay
  • EIA enzyme immunoassay
  • NIA nephelometric inhibition immunoassay
  • ELISA enzyme-linked immunosorbent assay
  • RIA radioimmunoassay
  • An indicator moiety, or label group may be attached to the subject antibodies and is selected so as to meet the needs of various uses of the method that are often dictated by the availability of assay equipment and
  • antibodies generated against the biomarkers of the invention can be used for visualizing for the presence of a protein of interest and can be labeled, for example, using a reporter molecule such as fluorophores, enzymes, biotin, chemiluminescent molecules, bioluminescent molecules, digoxigenin, avidin, streptavidin or radioisotopes.
  • a reporter molecule such as fluorophores, enzymes, biotin, chemiluminescent molecules, bioluminescent molecules, digoxigenin, avidin, streptavidin or radioisotopes.
  • Those patients that are determined to have an increased level of biomarker protein product compared to a control are referred to herein as having positive biomarker expression.
  • the solid malignancies are from a cancer selected from liver cancer, breast cancer, glioblastoma, prostate cancer, rhabdomyosarcoma, gastric cancer, ovarian cancer, lung cancer, colon cancer.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the present invention or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers for use in the treatment of solid malignancies characterized by positive FGFR4 and KLB expression, or by positive FGFR4 and FGF19 expression, or by positive FGFR4, KLB and FGF19 expression.
  • the invention relates to a method of treating cancer, comprising selectively administering a pharmaceutical composition comprising a compound of the present invention or a pharmaceutically acceptable salt thereof to a patient in need thereof on the basis of said patient having positive FGFR4 and KLB expression, or positive FGFR4 and FGF19 expression, or positive FGFR4, KLB and FGF19 expression.
  • the cancer is selected from liver cancer, breast cancer, glioblastoma, prostate cancer, rhabdomyosarcoma, gastric cancer, ovarian cancer, lung cancer, colon cancer.
  • the composition comprises at least two pharmaceutically acceptable carriers, such as those described herein.
  • pharmaceutically acceptable carriers are sterile.
  • the pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and rectal administration, etc.
  • the pharmaceutical compositions of the present invention can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions).
  • compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc.
  • the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with one or more of:
  • diluents e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine
  • lubricants e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol
  • binders e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone
  • disintegrants e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures
  • absorbents, colorants, flavors and sweeteners e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine
  • lubricants e.g., silica, talcum, stearic acid, its magnesium or
  • the pharmaceutical compositions are capsules comprising the active ingredient only.
  • Tablets may be either film coated or enteric coated according to methods known in the art.
  • compositions for oral administration include an effective amount of a compound of the invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs, solutions or solid dispersion.
  • compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
  • Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
  • compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions.
  • Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
  • Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.
  • compositions for transdermal application include an effective amount of a compound of the invention with a suitable carrier.
  • Carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host.
  • transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
  • compositions for topical application include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for delivery by aerosol or the like.
  • Such topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like.
  • Such are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art.
  • Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
  • topical application may also pertain to an inhalation or to an intranasal application.
  • a dry powder either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids
  • a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant.
  • the pharmaceutical composition used in the present invention can be in unit dosage of about 1-1000 mg of active ingredient(s) for a subject of about 50-70 kg, or about 1-500 mg or about 1-250 mg or about 1-150 mg or about 0.5-100 mg, or about 1-50 mg of active ingredients.
  • the therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
  • the compounds of the present invention can be produced by organic synthesis methods known to one of ordinary skill in the art as shown in the following examples.
  • NMR Measurements were performed on a Bruker UltrashieldTM 400 (400 MHz), Bruker UltrashieldTM 600 (600 MHz), 400 MHz DRX Bruker CryoProbe (400 MHz) or a 500 MHz DRX Bruker CryoProbe (500 MHz) spectrometer using or not trimethylsilane as an internal standard. Chemical shifts (d-values) are reported in ppm downfield from tetramethylsilane, spectra splitting pattern are designated as singlet (s), doublet (d), triplet (t), quartet (q), multiplet, unresolved or more overlapping signals (m), broad signal (br). Solvents are given in parentheses.
  • DSC DSC measurements were performed using a DSC Q2000 (TA Instruments, New Castle, Del., USA) equipped with a DSC Refrigerated Cooling System (TA Instruments, New Castle, Del., USA).
  • the crude material was purified by normal phase chromatography (4 g silica gel cartridge, heptanes/EtOAc 100:0 to 0:100) followed by a reverse phase chromatography (13 g C18 cartridge, 0.1% TFA in water/acetonitrile 80:20 to 0:100).
  • the product containing fractions were treated with sat. aq. Na 2 CO 3 , concentrated until the organic solvent had been removed extracted with DCM (3 ⁇ ).
  • the combined organic layers were dried over Na 2 SO 4 , filtered and evaporated to give the title compound as a colorless resin. (UPLC-MS 3) t R 0.92 min; ESI-MS 384.1 [M+H] + .
  • reaction mixture was quenched by addition of sat. aq. NH 4 Cl, warmed to room temperature and extracted with EtOAc (2 ⁇ ). The combined organic layers were washed with brine, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • the residue was purified by normal phase chromatography (12 g silica gel cartridge, heptanes/EtOAc 100:0 to 0:100) the 7-(dimethoxymethyl)-6-formyl-N-(5-(trifluoromethyl)pyridin-2-yl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide containing fractions were concentrated to give a white solid.
  • a tube was charged with methylamine hydrochloride (7.79 mg, 0.115 mmol) followed by methylamine (2 M in MeOH, 0.058 ml, 0.115 mmol) and NaCNBH 3 (14.5 mg, 0.231 mmol). Then, a suspension of N-(5-cyanopyridin-2-yl)-7-(dimethoxymethyl)-6-formyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide (intermediate 36, 22 mg, 0.058 mmol) in MeOH (1 ml) was added, the tube was sealed and the reaction mixture was stirred at 70° C. for 1 h.
  • the resulting solution was stirred with cooling for 35 min. The cooling bath was then removed and the reaction mixture was allowed to warm to ⁇ 25° C., before being re-cooled to ⁇ 70° C. The resulting solution was quenched with sat. aq. NH 4 Cl, allowed to warm to room temperature and extracted twice with EtOAc/heptanes 1:1. The combined organic layers were washed with brine, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. The crude material was purified by normal phase chromatography (80 g silica gel cartridge, heptanes/EtOAc 100:0 to 0:100). The product containing fractions were concentrated and dried under vacuum to give the title compound as a white solid.
  • N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide (6.5 g, 12.83 mmol) was placed in a 500 ml 4-flask reactor. 49 ml of glacial acetic acid was added and the resulting suspension was stirred at 23° C. until a clear mixture was obtained.
  • anhydrous 2-hydroxypropane-1,2,3-tricarboxylic acid (2.59 g, 13.47 mmol, 1.05 equiv.) was dissolved in 49 ml of glacial acetic acid at 50° C. until a clear solution was obtained. This solution was then added at 23° C. to the N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide solution previously prepared. This mixture was stirred for 30 min at 23° C.
  • reaction mixture was allowed to warm to room temperature and after a further 90 minutes at room temperature a solution of 1-((2-(dimethoxymethyl)-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)methyl)-4-methylpiperazin-2-one (intermediate 81, 418 mg, 1.00 mmol) in DMF (2 ml) was added.
  • the reaction mixture was stirred for 17.5 h at room temperature, quenched by the addition of MeOH and evaporated. The residue was applied to a 80 g RediSep® silica column as a DCM solution and purified by normal phase chromatography, eluting with a gradient from DCM to 2% MeOH in DCM.
  • Tartrate salt with 1:1 stoichiometry (mw 641.63): A solution of L-(+)-tartaric acid in acetone (0.1 M, 2.03 ml, 0.203 mmol) was added to a suspension of N-(5-cyano-4-isopropoxypyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide (100 mg, 0.203 mmol) in acetone (5 ml) at room temperature. The mixture was warmed to 55° C., maintained at this temperature for 3 h and cooled slowly to room temperature. The white precipitate that formed was washed with acetone and dried to give the title compound.
  • Tosylate salt with 1:1 stoichiometry (mw 663.75): A solution of tosic acid in acetone (0.1 M, 2.03 ml, 0.203 mmol) was added to a suspension of N-(5-cyano-4-isopropoxypyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide (100 mg, 0.203 mmol) in acetone (5 ml) at room temperature. The mixture was warmed to 55° C., maintained at this temperature for 3 h and cooled slowly to room temperature.
  • Citrate salt with 1:1 stoichiometry (mw 683.68): A solution of citric acid in acetone (0.1 M, 2.03 ml, 0.203 mmol) was added to a suspension of N-(5-cyano-4-isopropoxypyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide (100 mg, 0.203 mmol) in DCM (2 ml) at room temperature. The mixture was warmed with a bath at 65° C., maintained at this temperature for 10 min and slowly cooled to 5° C. The white precipitate that formed was collected, acetone (5 ml) and EtOH (1 ml) were added and the mixture heated at 50° C. for 3 h. The mixture was cooled to 5° C., filtered and dried to give the title compound.
  • reaction mixture was evaporated and applied to a 24 g RediSep silica column as a DCM solution and purified by normal phase chromatography, eluting with a gradient from DCM to 10% MeOH in DCM. Product containing fractions were combined and evaporated to give the title compound as an off-white solid.
  • Phenyl chloroformate (3.89 ml, 31.0 mmol) was added drop wise to a mixture of 6-amino-4-isopropoxynicotinonitrile (intermediate 97, 2.5 g, 14.11 mmol) and pyridine (2.51 ml, 31.0 mmol) in THF (100 ml) at room temperature.
  • the reaction mixture was stirred for 12 h at room temperature, additional pyridine (2.51 ml, 31.0 mmol) added, before stirring for an additional 12 h and then partitioned between EtOAc and saturated aqueous NaHCO 3 solution.
  • the organic layer was washed with saturated brine, dried over MgSO 4 and evaporated.
  • the residue was triturated with Et 2 O and the product obtained by filtration as a beige solid.
  • UPLC-MS 7 t R 1.09; ESI-MS 298.2 [M+H] + .
  • the reaction mixture was stirred for 21 h at room temperature and additional sodium triacetoxyborohydride (2.6 g, 9.74 mmol) was added. After a further 4 h stirring at room temperature, again additional sodium triacetoxyborohydride (1.3 g, 4.87 mmol) was added and the reaction maintained at 4° C. for 2.5 days. The reaction mixture was then warmed to room temperature, saturated aqueous NaHCO 3 solution added, the mixture extracted with DCM (3 ⁇ ), the combined organic layers dried over Na 2 SO 4 and evaporated. The residue was applied to a 120 g RediSep® silica column as a DCM solution and purified by normal phase chromatography, eluting with a gradient from DCM to 10% MeOH in DCM.
  • Citrate salt with 1:1 stoichiometry (mw 699.68): A solution of citric acid (0.1 M, 1.97 ml, 0.197 mmol) was added to a suspension of N-(5-cyano-4-(2-methoxyethoxy)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide (100 mg, 0.197 mmol) in acetone (5 ml) at room temperature. The mixture was stirred at 55° C. for 3 h, cooled slowly to room temperature, the white precipitate collected by filtration and dried under vacuum to give the title compound.
  • Phenyl chloroformate (4.93 ml, 39.3 mmol) was added drop wise to a mixture of 6-amino-4-(2-methoxyethoxy)nicotinonitrile (intermediate 20, 3.45 g, 17.86 mmol) and pyridine (6.35 ml, 79 mmol) in THF (100 ml) at room temperature.
  • the reaction mixture was stirred for 5 h at room temperature and then partitioned between EtOAc and saturated aqueous NaHCO 3 solution, the organic layer washed with saturated brine, dried over MgSO 4 and evaporated. The residue was triturated with EtOAc and the product obtained by filtration as a white solid.
  • UPLC-MS 7 t R 0.97; ESI-MS 314.3 [M+H] + .
  • Example 205 (R)—N-(5-cyano-4-((1-methoxypropan-2-yl)oxy)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
  • Tosylate with 1:1 stoichiometry (mw 693.78): A solution of tosic acid in acetone (0.1 M, 2.0 ml, 0.200 mmol) was added to a suspension of (R)—N-(5-cyano-4-((1-methoxypropan-2-yl)oxy)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide (100 mg, 0.192 mmol) in acetone (4 ml) at room temperature.
  • Citrate with 1:1 stoichiometry (mw 713.71): A solution of citric acid in acetone (0.1 M, 2.0 ml, 0.200 mmol) was added to a suspension of (R)—N-(5-cyano-4-((1-methoxypropan-2-yl)oxy)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide (100 mg, 0.192 mmol) in acetone (4 ml) at room temperature.
  • the mixture was warmed to 55° C., maintained at this temperature for 2.5 h with sonication and then cooled slowly to room temperature. After standing 18 h at 5° C. the solid was collected by filtration, washed with acetone and then dried under vacuum to give the title compound.
  • Phenyl chloroformate (1.53 ml, 12.2 mmol) was added drop wise to a mixture of (R)-6-amino-4-((1-methoxypropan-2-yl)oxy)nicotinonitrile (intermediate 146, 1.37 g, 5.55 mmol) and pyridine (0.99 ml, 12.2 mmol) in THF (60 ml) at 0° C. The reaction mixture was stirred for 12 h at room temperature and additional pyridine (0.98 ml, 12.2 mmol) and phenyl chloroformate (1.53 ml, 12.2 mmol) were added.
  • a microwave vial was charged with a mixture of tert-butyl 2-formyl-7,8-dihydro-5H-pyrido[2,3-b]azepine-9(6H)-carboxylate (intermediate 238, 415 mg, 1.277 mmol) and p-toluenesulfonic acid monohydrate (110 mg, 0.573 mmol) in MeOH (64 ml), sealed and then heated at 135° C. for 3.5 h. The reaction mixture was concentrated and the residue partitioned between sat. aq. NaHCO 3 and EtOAc. The aq. phase was extracted with EtOAc (2 ⁇ )—the combined organic layers were dried over Na 2 SO 4 and evaporated.
  • MFS Methylene Blue Staining Proliferation Assay
  • HuH-7 hepatocellular carcinoma cells obtained from the Japanese Collection of Research Bioresources Cell Bank (Cat# JCRB0403) and cultured in the vendor-recommended medium (DMEM high glucose (Amimed Cat#1-26F01-1), 10% foetal calf serum (Invitrogen Cat#16140-071), 1 mM sodium pyruvate (Amimed Cat#5-60F00-H), 1 ⁇ Penicillin/Streptomycin (Amimed Cat#4-01F00-H)) at 37° C. in a humidified 5% CO2 incubator.
  • DMEM high glucose Amimed Cat#1-26F01-1
  • 10% foetal calf serum Invitrogen Cat#16140-071
  • 1 mM sodium pyruvate Amimed Cat#5-60F00-H
  • Penicillin/Streptomycin Amimed Cat#4-01F00-H
  • 5000 cells/well were seeded in 96-well tissue culture plates (TPP Cat#92696) in a total media volume of 100 ⁇ l/well and increasing compound dilutions or DMSO were added 24 hours thereafter in triplicates. 72 hours after compound addition, cells were fixed by adding 25 ⁇ L/well of 20% glutaraldehyde (Sigma Aldrich Cat# G400-4) and incubated for 10 minutes at room temperature. Cells were washed three times with H 2 O, 200 ⁇ L/well and stained with 100 ⁇ L/well 0.05% methylene blue (ABCR GmbH Cat# AB117904) for 10 minutes at room temperature.
  • Hep 3B2.1-7 hepatocellular carcinoma cells FU97 gastric cancer cells, JHH7 hepatocellular carcinoma cells or JHH6 hepatocellular carcinoma cells is assessed as above.
  • Hep 3B2.1-7, FU97, JHH7 or JHH6 are obtained from the Japanese Collection of Research Bioresources Cell Bank.
  • Hep 3B2.1-7 cells are cultured in EMEM+10% FCS+1 mM Na pyruvate+2 mM L-glutamine and 2000 cells/well are seeded for the proliferation assay.
  • FU97 cells are cultured in DMEM high glucose+10% FCS+1 mM Na pyruvate+4 mM L-glutamine+1 ⁇ ITS and 2000 cells/well are seeded for the proliferation assay.
  • JHH6 and JHH7 cells are cultured in William's E+10% FCS+2 mM L-glutamine and 3000 cells are seeded for the proliferation assay.
  • HuH-7 hepatocellular carcinoma cells obtained from the Japanese Collection of Research Bioresources Cell Bank (Cat# JCRB0403) and cultured in the vendor-recommended medium (DMEM high glucose (Amimed Cat#1-26F01-I), 10% foetal calf serum (Invitrogen Cat#16140-071), 1 mM sodium pyruvate (Amimed Cat#5-60F00-H), 1 ⁇ Penicillin/Streptomycin (Amimed Cat#4-01F00-H)) at 37° C. in a humidified 5% CO2 incubator.
  • DMEM high glucose Amimed Cat#1-26F01-I
  • 10% foetal calf serum Invitrogen Cat#16140-071
  • 1 mM sodium pyruvate Amimed Cat#5-60F00-H
  • Penicillin/Streptomycin Amimed Cat#4-01F00-H
  • Compound-mediated suppression of cell proliferation/viability is assessed by quantification of cellular ATP levels using the CellTiter-Glo (CTG) reagent (Promega, Cat# G7573). Briefly, cells are seeded at 3′000 cells/well/80 ⁇ l fresh medium into tissue-culture-treated 96-well plates (Costar Cat#3904), followed by addition of 20 ⁇ l medium containing compound dilutions at 5-fold their final intended concentration. Dose-response effects are assessed by 3-fold serial dilutions of the test compound, starting at 10 ⁇ M. Following incubation of the cells for 3 days at 37° C.
  • CCG CellTiter-Glo
  • the effect of inhibitors on cell viability is quantified following addition of 50 ⁇ l CTG and luminescence measurement (integration time: 500 ms) as per vendor manual, using a correspondingly equipped multi-mode plate reader (M200Pro, TECAN, Switzerland).
  • integration time 500 ms
  • M200Pro multi-mode plate reader
  • the assay background value determined in wells containing medium, but no cells, is subtracted from all data points.
  • the number of viable cells is assessed relative to that observed at the time of compound addition using a separate cell plate (day 0).
  • the effect of a particular test compound concentration on cell proliferation/viability is expressed as percentage of the background- and day 0-corrected luminescence reading obtained for cells treated with vehicle only (DMSO, 0.1% f.c.), which is set as 100%, whereas the luminescence reading for wells containing medium only, but no cells, is set as ⁇ 100%.
  • Compound concentrations leading to half-maximal growth inhibition (GI50) are determined using standard four parameter curve fitting (XLfit 5.2., IDBS, UK).
  • the compounds can be tested in the following in vivo assay.
  • Tumor response was quantified by calculating the change in tumor volume (endpoint minus starting value) as the T/C, i.e. ( ⁇ TVoldrug/ ⁇ TVolvehicle ⁇ 100). In the case of tumor regression, the tumor response was quantified by the percentage of regression of the starting tumor volume, i.e. ( ⁇ TVoldrug/ ⁇ TVolday0 ⁇ 100).
  • Statistical analysis was performed by comparing the treatment groups to the vehicle control group at endpoint using Kruskal-Wallis followed by Dunn's post hoc test. At least one compound of the invention showed 70% tumour regression.
  • FGF19 protein levels are measured using the human FGF-19 DuoSet DY969 from R&D Systems following the indications of the manufacturer.
  • the capture antibody was diluted in PBS to a working dilution of 4 ⁇ g/mL and used to coat a 96-well plate (Costar #2592) with 100 ⁇ l/well at room temperature overnight. Plates were washed 6 times with 400 ⁇ l/well of PBS/0.05% Tween20 and blocked by adding 300 ⁇ l/well of assay diluent (1% BSA in PBS) for 2 hours at room temperature. Plates were washed 6 times with 400 ⁇ l/well of PBS/0.05% Tween20.
  • Cell lines were lysed using MPER lysis buffer (Pierce #78501) supplemented with Complete protease inhibitor tablets (Roche #11836145001) and PhosStop phosphatase inhibitor tablets (Roche #04906837001) on ice for 30 minutes. Lysates were clarified by centrifugation at 12000 ⁇ g for 15 minutes and protein concentration was determined using the DC protein assay reagents (Bio Rad #500-0116) and a BSA standard. Cell lysates were diluted in PBS/1% BSA to add 100 ⁇ g/well and 10 ⁇ g/well in 100 ⁇ L. A 7-points standard ranging from 1000 ⁇ g/mL to 15.625 ⁇ g/mL was prepared. Samples and standards were added onto the coated plate, covered with a plate sealer and incubated for 2 hours on a plate mixer followed by 4 washings with 400 ⁇ l/well of PBS/0.05% Tween20.
  • the detection antibody diluted to a working concentration of 100 ng/mL in PBS/1% BSA, was added in 100 ⁇ l/well and incubated at room temperature for 2 hours on a plate mixer followed by 4 washings with 400 ⁇ l/well of PBS/0.05% Tween20.
  • the streptavidin solution diluted in PBS/1% BSA was added onto the plate and incubated at room temperature, protected from light for 20 minutes followed by 3 washing with 400 ⁇ l/well of PBS/0.05% Tween20.
  • the optical density of the plate was determined using a microplate reader set at 450 nm.
  • FGFR4 protein levels are quantified by performing sandwich-type capture ELISA on cell lysate. Cells were lysed as above.
  • 96-well ELISA plates (NUNC #437111) were pre-coated with mouse anti-FGFR4 mAb (R&D Systems #MAB685), 100 ⁇ l each diluted 1:100 in PBS without Ca2+/Mg2+. Following incubation for 1 hour at room temperature on an orbital shaker, 150 ⁇ l 3% MSD blocker A (MesoScale Discovery #R93BA-4) in TBS complemented with 0.05% Tween-20 (TBST-T) was added for 1 hour at room temperature. The wells were washed with 3 changes of 200 ⁇ l TBST-T.
  • MSD blocker A MesoScale Discovery #R93BA-4
  • Equal aliquots of the protein lysates were added to two pre-coated 96-well ELISA plates. Additional wells to assess the assay background were incubated with 100 ⁇ l lysis buffer/MSD Blocker A 1% (3:1) buffer mix. After an overnight incubation at 4° C., wells were washed with 3 changes of 200 ⁇ l TBS-T. ELISA-plates pre-coated with the capture antibody were then incubated for 1.5 hours with 100 ⁇ l rabbit anti-FGFR4 mAb (Cell Signaling Technology #8562) diluted 1:1000 in 1% MSD blocking buffer at room temperature on an orbital shaker.
  • 100 ⁇ l rabbit anti-FGFR4 mAb Cell Signaling Technology #8562
  • KLB protein levels are quantified by western blot.
  • Cells were lysed as above. 50 ⁇ g of cell lysates were loaded onto 4-12% gradient NuPAGE Bis-Tris gels (Invitrogen #WG1402BX10) and blotted onto PVDF membranes. Filters were blocked in 5% milk for 1 hour at room temperature. The primary anti-human Klotho- ⁇ antibody (R&D Systems #AF5889) was used at 2 ⁇ g/mL. Signal detection was done using a secondary anti-goat-HRP antibody (Sigma #A5420).
  • 1-tubulin was used as an internal control, and the detection was performed with anti- ⁇ -tubulin antibody (Sigma clone 2.1) followed by a secondary anti-mouse-HRP antibody (Amersham NA931). Membranes were imaged using the Fusion FX7 imaging system, and KLB levels were expressed as % of 3-tubulin levels. The detection was done with super-signal west dura substrate (Thermo Signal, #34076).
  • FGF19 FGFR4 Cell line (pg/mL) (luminescence units) KLB (% of ⁇ -tubulin) HUH7 1080 1305930 3.36 Hep3B 399 700932 4.13 JHH7 4410 537741 1.12 Fu97 841 1164087 6.39 JHH6 BLQ 853 BLQ BLQ indicates below limit of detection using the corresponding assay.
  • the compounds of the invention can be measured in a JHH6 cell proliferation assay (described above).
  • a compound of the invention measured in this assay showed an IC50>10000 nM.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
US15/516,443 2014-10-03 2015-10-02 Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors Abandoned US20180185341A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/088094 2014-10-03
CN2014088094 2014-10-03
PCT/US2015/053677 WO2016054483A1 (en) 2014-10-03 2015-10-02 Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/053677 A-371-Of-International WO2016054483A1 (en) 2014-10-03 2015-10-02 Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/190,087 Continuation US10463653B2 (en) 2014-10-03 2018-11-13 Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US16/289,612 Continuation US10507201B2 (en) 2014-10-03 2019-02-28 Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

Publications (1)

Publication Number Publication Date
US20180185341A1 true US20180185341A1 (en) 2018-07-05

Family

ID=54330059

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/516,443 Abandoned US20180185341A1 (en) 2014-10-03 2015-10-02 Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US16/190,087 Active US10463653B2 (en) 2014-10-03 2018-11-13 Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US16/289,612 Active US10507201B2 (en) 2014-10-03 2019-02-28 Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/190,087 Active US10463653B2 (en) 2014-10-03 2018-11-13 Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US16/289,612 Active US10507201B2 (en) 2014-10-03 2019-02-28 Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

Country Status (6)

Country Link
US (3) US20180185341A1 (enExample)
EP (1) EP3200786B1 (enExample)
JP (2) JP6585167B2 (enExample)
ES (1) ES2756748T3 (enExample)
PL (1) PL3200786T3 (enExample)
WO (1) WO2016054483A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10463653B2 (en) * 2014-10-03 2019-11-05 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234072B (zh) * 2016-05-20 2022-11-04 江苏豪森药业集团有限公司 Fgfr4抑制剂、其制备方法和应用
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
JP7394623B2 (ja) * 2016-11-02 2023-12-08 ノバルティス アーゲー Ｆｇｆｒ４インヒビターおよび胆汁酸捕捉薬の組合せ
TWI723480B (zh) * 2018-07-27 2021-04-01 大陸商北京加科思新藥研發有限公司 用作fgfr4抑制劑的稠環衍生物
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
US6140338A (en) 1996-07-29 2000-10-31 Banyu Pharmaceutical, Co., Ltd. Chemokine receptor antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
CO4980854A1 (es) 1998-02-10 2000-11-27 Novartis Ag Inhibidores de celulas b particularmente amidas, proceso par su produccion y composiciones farmaceuticas que los contiene
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
US6407241B1 (en) 1999-11-08 2002-06-18 Merck & Co., Inc. Process and intermediates for the preparation of imidazolidinone αv integrin antagonists
KR20020048427A (ko) * 1999-11-08 2002-06-22 폴락 돈나 엘. 이미다졸리디논 알파 ｖ 인테그린 길항제를 제조하기 위한방법 및 중간체
EP1475368A4 (en) 2002-02-14 2006-03-29 Ono Pharmaceutical Co FUSED CORE COMPOUNDS CONTAINING N-CARBAMOYL NITROGEN AND MEDICAMENTS CONTAINING SAID COMPOUNDS AS ACTIVE INGREDIENTS
JPWO2004007472A1 (ja) 2002-07-10 2005-11-17 小野薬品工業株式会社 Ｃｃｒ４アンタゴニストおよびその医薬用途
KR100732440B1 (ko) * 2002-08-30 2007-06-27 에자이 알앤드디 매니지먼트 가부시키가이샤 질소 함유 방향환 유도체
WO2004056820A1 (en) 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CA2517888C (en) 2003-03-14 2012-05-01 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
WO2004091485A2 (en) 2003-04-11 2004-10-28 Taigen Biotechnology Aminoquinoline compounds
CN102060806A (zh) 2003-09-11 2011-05-18 iTherX药品公司 细胞因子抑制剂
WO2007009883A1 (en) 2005-07-15 2007-01-25 F. Hoffmann-La Roche Ag Novel heteroaryl fused cyclic amines
EP1963320A1 (en) * 2005-12-07 2008-09-03 OSI Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
ME00011A (me) 2005-12-21 2009-02-10 Novartis Ag Derivati pirimidinilaril uree kao fgf inhibitori
CN101405002A (zh) 2005-12-29 2009-04-08 詹森药业有限公司 激肽原2受体拮抗剂
WO2007136893A2 (en) 2006-02-10 2007-11-29 Genentech, Inc. Anti-fgf19 antibodies and methods using same
KR20090008217A (ko) 2006-03-10 2009-01-21 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제
WO2007141473A1 (en) * 2006-06-09 2007-12-13 Astrazeneca Ab N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
WO2007146230A2 (en) 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
EP1918376A1 (en) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
MX2009009574A (es) 2007-03-09 2009-09-16 Novartis Ag Tratamiento de melanoma.
EP2550972B1 (en) 2007-04-02 2018-02-21 Genentech, Inc. A Klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
WO2009079008A1 (en) 2007-12-19 2009-06-25 Yangbo Feng Benzopyrans and analogs as rho kinase inhibitors
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
CN102224170A (zh) 2008-09-03 2011-10-19 利琴蒂亚有限公司 抑制与fgfr4相关的癌细胞侵袭的材料和方法
WO2010027002A1 (ja) 2008-09-05 2010-03-11 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する縮環モルホリン誘導体
CN102325531B (zh) 2008-12-19 2014-04-02 健泰科生物技术公司 化合物和使用方法
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
SG175877A1 (en) 2009-05-04 2011-12-29 Plexxikon Inc Compounds and methods for inhibition of renin, and indications therefor
JP2013509442A (ja) 2009-10-29 2013-03-14 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節因子としての二環式ピリジンおよび類似体
EP2493864B1 (en) 2009-10-30 2014-10-01 Novartis AG N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea
US20190192510A1 (en) 2010-02-01 2019-06-27 Nippon Chemiphar Co., Ltd. Gpr119 agonist
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
CA2806341C (en) 2010-07-29 2020-03-24 Rigel Pharmaceuticals, Inc. Ampk-activating heterocyclic compounds and methods for using the same
WO2012061337A1 (en) * 2010-11-02 2012-05-10 Exelixis, Inc. Fgfr2 modulators
JP5620417B2 (ja) * 2011-02-07 2014-11-05 中外製薬株式会社 アミノピラゾール誘導体を含む医薬
AP2013007153A0 (en) 2011-03-18 2013-09-30 Lupin Ltd Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators
KR20140021589A (ko) 2011-04-07 2014-02-20 제넨테크, 인크. 항-fgfr4 항체 및 사용 방법
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
BR112015000653A2 (pt) 2012-07-11 2019-11-05 Blueprint Medicines Corp compostos inibidores do receptor de fator de crescimento de fibroblasto, sua composição farmacêutica e seus usos
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014079709A1 (en) 2012-11-23 2014-05-30 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
AU2014228746B2 (en) 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
KR102469849B1 (ko) 2013-04-19 2022-11-23 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
EP3019491A4 (en) 2013-07-09 2016-12-21 Dana Farber Cancer Inst Inc KINASEHEMMER FOR THE TREATMENT OF DISEASES
TW201605452A (zh) 2013-08-28 2016-02-16 安斯泰來製藥股份有限公司 以嘧啶化合物作爲有效成分之醫藥組成物
SG11201602069WA (en) 2013-10-18 2016-04-28 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
DK3395814T3 (da) 2013-10-25 2022-07-04 Blueprint Medicines Corp Hæmmere af fibroblastvækstfaktorreceptoren
AU2014338549B2 (en) * 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP3200786B1 (en) * 2014-10-03 2019-08-28 Novartis AG Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US9802917B2 (en) * 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3273959A1 (en) * 2015-03-25 2018-01-31 Novartis Ag Pharmaceutical combinations
JP7394623B2 (ja) 2016-11-02 2023-12-08 ノバルティス アーゲー Ｆｇｆｒ４インヒビターおよび胆汁酸捕捉薬の組合せ

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10463653B2 (en) * 2014-10-03 2019-11-05 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US10507201B2 (en) 2014-10-03 2019-12-17 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

Also Published As

Publication number Publication date
WO2016054483A1 (en) 2016-04-07
JP2019218398A (ja) 2019-12-26
US20190076412A1 (en) 2019-03-14
US10463653B2 (en) 2019-11-05
US10507201B2 (en) 2019-12-17
PL3200786T3 (pl) 2020-03-31
JP6585167B2 (ja) 2019-10-02
JP6794514B2 (ja) 2020-12-02
EP3200786B1 (en) 2019-08-28
EP3200786A1 (en) 2017-08-09
US20190231760A1 (en) 2019-08-01
ES2756748T3 (es) 2020-04-27
JP2017530154A (ja) 2017-10-12

Similar Documents

Publication Publication Date Title
US10507201B2 (en) Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US9266883B2 (en) Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
CA2926328C (en) Substituted quinazolinyl and quinolinyl derivatives and pharmaceutical compositions thereof useful as inhibitors of kras g12c
US10238652B2 (en) Compounds for treatment of cancer
JP6771464B2 (ja) Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
US10512626B2 (en) Compositions for use in treating glioblastoma
US8278337B2 (en) Substituted pyridines that are JNK inhibitors
US20250129096A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20250296940A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
JP6898919B2 (ja) 新規化合物
JP2011513483A (ja) タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
TW201734005A (zh) 用於治療纖維化之新穎化合物及其醫藥組合物
WO2020125513A1 (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
JP2022526364A (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
JP2022526176A (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
KR20180073681A (ko) 1,4-디카르보닐-피페리딜 유도체
US7943654B2 (en) 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
TWI690528B (zh) 稠環雙環吡啶基衍生物
US20250376445A1 (en) Compounds and methods for yap/tead modulation and indications therefor
HK1222388B (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
HK1174038A (en) 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase
HK1254965B (zh) 新化合物

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SUZHOU NOVARTIS PHARMA TECHNOLOGY CO., LTD.;REEL/FRAME:043431/0507

Effective date: 20151126

Owner name: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PALMER, MICHAEL;PORTER, DALE;WANG, YOUZHEN;SIGNING DATES FROM 20151105 TO 20160107;REEL/FRAME:043431/0325

Owner name: NOVARTIS PHARMA AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BUSCHMANN, NICOLE;FAIRHURST, ROBIN ALEC;FURET, PASCAL;AND OTHERS;SIGNING DATES FROM 20151109 TO 20151214;REEL/FRAME:043431/0087

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BEIJING NOVARTIS PHARMA CO. LTD.;REEL/FRAME:043431/0222

Effective date: 20151126

Owner name: SUZHOU NOVARTIS PHARMA TECHNOLOGY CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAN, BO;WANG, CAN;ZHAO, XIANGLIN;REEL/FRAME:043431/0443

Effective date: 20151124

Owner name: BEIJING NOVARTIS PHARMA CO. LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIAO, LV;XIONG, JING;SIGNING DATES FROM 20151116 TO 20151117;REEL/FRAME:043431/0212

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS PHARMA AG;REEL/FRAME:043431/0141

Effective date: 20160113

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.;REEL/FRAME:043707/0927

Effective date: 20160107

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE